PALO
ALTO, Calif., July 18,
2022 /PRNewswire/ -- Eiger BioPharmaceuticals,
Inc. (Nasdaq: EIGR), a commercial-stage
biopharmaceutical company focused on the development of innovative
therapies to treat and cure hepatitis delta virus
(HDV) and other serious diseases, today announced the
appointment of Lisa Kelly-Croswell to its Board of
Directors.
Ms. Kelly-Croswell is an accomplished senior human resources and
organizational executive and brings nearly 25 years of experience
in the biopharmaceutical and life sciences industries. She is
currently Senior Vice President and Chief Human Resources Officer
at Boston Medical Center Health System, where she oversees the
organizational agenda for a $5
billion health system, full-service academic medical center,
and 450,000-member managed healthcare plan.
"Lisa's extensive experience in biopharmaceuticals and
healthcare systems alongside her track record in leading meaningful
organizational growth ideally position her to bring an important
perspective to our board," said Thomas
Dietz, PhD, Chairman of the Board, Eiger. "As a seasoned
executive in the healthcare field, her insights and perspective
will be a valuable addition to our strategic planning process for
the future Eiger organization and late-stage pipeline announcements
ahead."
Prior to her leadership position with the Boston Medical Center
Health System, Ms. Kelly-Croswell led Human Resources for Vertex
Pharmaceuticals, playing a pivotal role in the company's
transformation from a research organization into a fully
sustainable commercial biotechnology company. Before Vertex, Ms.
Kelly-Croswell held roles within Nitromed, Cigna, and Monsanto. She
currently serves on the board of Synlogic and is a current and
past board member of multiple non-profit organizations.
"I am delighted to join the Eiger board at this exciting time in
its evolution to a commercial stage biopharmaceutical company,"
said Ms. Kelly-Croswell. "The company's progress to date has
been impressive and the diverse pipeline with breakthrough therapy
programs is most promising for patients that may ultimately
benefit. I look forward to being part of Eiger's future growth and
continued success."
Ms. Kelly-Croswell holds an MA in Labor and Industrial Relations
and a BA in Finance from the University of
Illinois at Urbana-Champaign. She is the holder of the 2022
NEHRA Diversity Champion Award and is a 2021 awardee for
Boston's Most Impactful Black
Women. She has been featured in the Boston Business Journal and
Forbes and is a sought-after speaker and panelist for many
organizational conferences and events.
About Eiger
Eiger is a commercial-stage biopharmaceutical company focused on
the development of innovative therapies to treat and cure hepatitis
delta virus (HDV) and other serious diseases. The Eiger HDV
platform includes two first-in-class therapies in Phase 3 that
target critical host processes involved in viral replication. Eiger
is also developing peginterferon lambda as a therapeutic for
COVID-19 and reported positive results from TOGETHER, a
Phase 3 investigator-initiated study.
All five Eiger rare disease programs have been granted FDA
Breakthrough Therapy designation: lonafarnib and peginterferon
lambda for HDV, Zokinvy for progeria, and avexitide for both
congenital hyperinsulinism and post-bariatric hypoglycemia.
For additional information about Eiger and its clinical
programs, please visit www.eigerbio.com.
Contacts
Investors:
Sylvia Wheeler
Wheelhouse Life Science Advisors
swheeler@wheelhouselsa.com
Media:
Sarah Mathieson
SVP, Corporate Affairs
smathieson@eigerbio.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/eiger-appoints-senior-human-resources-and-organizational-executive-lisa-kelly-croswell-to-board-of-directors-301587947.html
SOURCE Eiger BioPharmaceuticals, Inc.